Paul Robbins, MD
Psychiatry · Summerville, SCNPI 1780757237
Payments from drug & device makers
Across 242 payments — averaging $5069.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$644K
- AbbVie$221K
- Janssen Research & Development, LLC$101K
- Supernus Pharmaceuticals, Inc.$80K
- Acadia Pharmaceuticals Inc$56K
- Shire North American Group Inc$52K
- plus $72K from 11 others
Across 13 payments — averaging $7699.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Arbor Pharmaceuticals, Inc.$99K
- AbbVie$1K
What the payments were for
- Speaking & faculty fees$2,25033%
- Travel & lodging$95714%
- Food & beverage$3,70954%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 10 | $644,268 |
| AbbVie(2 entities) | 79 | $221,273 |
| Janssen Research & Development, LLC | 10 | $100,840 |
| Supernus Pharmaceuticals, Inc. | 22 | $80,499 |
| Acadia Pharmaceuticals Inc | 21 | $55,595 |
| Shire North American Group Inc | 16 | $52,168 |
| F. Hoffmann-la Roche AG | 6 | $47,251 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $13,426 |
| Sunovion Pharmaceuticals Inc. | 20 | $5,912 |
| Johnson & Johnson | 25 | $4,444 |
| Neurocrine Biosciences, Inc. | 7 | $405 |
| Teva Pharmaceuticals USA, Inc. | 5 | $295 |
| E.r. Squibb & Sons, L.L.C. | 3 | $251 |
| Alkermes, Inc. | 5 | $88 |
| Vanda Pharmaceuticals Inc. | 3 | $54 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Vertical Pharmaceuticals, LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$3,799
- LATUDA$353
- VRAYLAR$342
- INGREZZA$256
- COBENFY$226
- AUSTEDO$125
- INVEGA SUSTENNA$122
- INVEGA TRINZA$122
- Austedo XR$120
How this compares
$1,226,841 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 23 | $209,164 |
| Invega SustennaPaliperidone Palmitate | 70 | $205,013 |
| UzedyRisperidone | 22 | $46,277 |
| Abilify MaintenaAripiprazole | 16 | $46,221 |
| AristadaAripiprazole Lauroxil | 12 | $38,269 |
| RexultiBrexpiprazole | 13 | $22,136 |
| Aripiprazole | 61 | $5,387 |
| Paliperidone ErPaliperidone | 25 | $2,850 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $800 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 11 | $710 |
| Ziprasidone Hcl | 28 | $550 |
| Lurasidone Hcl | 14 | $465 |
| Quetiapine Fumarate | 60 | $413 |
| Alprazolam ErAlprazolam | 11 | $397 |
| Benztropine Mesylate | 32 | $336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $4,444 | $414,17793 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $51 | $68,35729 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $295 | $46,27722 claims |
| Alkermes, Inc.Aristada | $88 | $38,26912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Summerville
- Jacobo MintzerCharleston$4.9M
- Brittany AlbrightMount Pleasant$691K
- Eduardo CifuentesCharleston$675K
- Veronica RidpathFlorence$364K
- Mark GeorgeCharleston$332K
- Jagdish ShahRock Hill$320K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
- Thomas UhdeCharleston$205K
- Jeffrey StephensGreenville$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.